All six treatments — Abecma, Breyanzi, Carvykti, Kymriah, Yescarta and Tecartus —will carry the warning. However, the FDA sent a revised letter to Kite for its therapy, Tecartus, removing the requirement to state that secondary cancers have occurred in patients who took the therapy because it hasn't identified any cases. It's unclear how or if the newly identified risk will affect the burgeoning CAR-T market, which is poised to expand beyond oncology and may generate $35.9 billion by 2032.